KURA ONCOLOGY INC (KURA) Stock Fundamental Analysis
USA - NASDAQ:KURA - US50127T1097 - Common Stock
10.465 USD
+0.77 (+7.89%)
KURA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While KURA seems to be doing ok healthwise, there are quite some concerns on its profitability. KURA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year KURA has reported negative net income.
In the past year KURA had a positive cash flow from operations.
KURA had negative earnings in each of the past 5 years.
KURA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of KURA (-28.89%) is better than 67.98% of its industry peers.
KURA has a better Return On Equity (-64.54%) than 60.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.89% | ||
| ROE | -64.54% | ||
| ROIC | N/A |
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for KURA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KURA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KURA has been increased compared to 1 year ago.
KURA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KURA has been reduced compared to a year ago.
2.2 Solvency
KURA has an Altman-Z score of -0.72. This is a bad value and indicates that KURA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KURA (-0.72) is comparable to the rest of the industry.
The Debt to FCF ratio of KURA is 0.08, which is an excellent value as it means it would take KURA, only 0.08 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.08, KURA belongs to the best of the industry, outperforming 96.63% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that KURA is not too dependend on debt financing.
KURA's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. KURA outperforms 42.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Altman-Z | -0.72 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
A Current Ratio of 6.16 indicates that KURA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.16, KURA is in the better half of the industry, outperforming 64.23% of the companies in the same industry.
A Quick Ratio of 6.16 indicates that KURA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.16, KURA is in the better half of the industry, outperforming 64.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.16 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
KURA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.35%.
EPS 1Y (TTM)-1.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, KURA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.89% on average per year.
The Revenue is expected to grow by 147.84% on average over the next years. This is a very strong growth
EPS Next Y-25.5%
EPS Next 2Y-12.04%
EPS Next 3Y-7.88%
EPS Next 5Y22.89%
Revenue Next Year948.03%
Revenue Next 2Y403.19%
Revenue Next 3Y184.91%
Revenue Next 5Y147.84%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
KURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KURA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
KURA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KURA is cheaper than 99.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.39 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as KURA's earnings are expected to decrease with -7.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.04%
EPS Next 3Y-7.88%
5. Dividend
5.1 Amount
No dividends for KURA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KURA (10/27/2025, 2:12:05 PM)
10.465
+0.77 (+7.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.83%
Inst Owner Change0.69%
Ins Owners1.29%
Ins Owner Change6.02%
Market Cap908.36M
Revenue(TTM)83.28M
Net Income(TTM)-197172000
Analysts82.86
Price Target27.54 (163.16%)
Short Float %12.56%
Short Ratio5.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-62.9%
Min EPS beat(2)-65.56%
Max EPS beat(2)-60.23%
EPS beat(4)2
Avg EPS beat(4)-14.58%
Min EPS beat(4)-65.56%
Max EPS beat(4)66.19%
EPS beat(8)5
Avg EPS beat(8)-5.36%
EPS beat(12)9
Avg EPS beat(12)-0.33%
EPS beat(16)13
Avg EPS beat(16)1.4%
Revenue beat(2)1
Avg Revenue beat(2)-23.89%
Min Revenue beat(2)-59.12%
Max Revenue beat(2)11.33%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.18%
EPS NQ rev (1m)-1.7%
EPS NQ rev (3m)-21.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.02%
Revenue NQ rev (1m)423.24%
Revenue NQ rev (3m)230.49%
Revenue NY rev (1m)5.27%
Revenue NY rev (3m)-25.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.91 | ||
| P/FCF | 7.39 | ||
| P/OCF | 7.27 | ||
| P/B | 2.97 | ||
| P/tB | 2.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.26
EYN/A
EPS(NY)-2.55
Fwd EYN/A
FCF(TTM)1.42
FCFY13.53%
OCF(TTM)1.44
OCFY13.76%
SpS0.96
BVpS3.52
TBVpS3.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.89% | ||
| ROE | -64.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 147.53% |
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 241.96% | ||
| Cap/Sales | 2.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.16 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | -0.72 |
F-Score6
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)52.78%
Cap/Depr(5y)301.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.12%
EPS Next Y-25.5%
EPS Next 2Y-12.04%
EPS Next 3Y-7.88%
EPS Next 5Y22.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year948.03%
Revenue Next 2Y403.19%
Revenue Next 3Y184.91%
Revenue Next 5Y147.84%
EBIT growth 1Y-9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.22%
EBIT Next 3Y-16.78%
EBIT Next 5Y2.08%
FCF growth 1Y212.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y214.64%
OCF growth 3YN/A
OCF growth 5YN/A
KURA ONCOLOGY INC / KURA FAQ
What is the ChartMill fundamental rating of KURA ONCOLOGY INC (KURA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KURA.
What is the valuation status for KURA stock?
ChartMill assigns a valuation rating of 2 / 10 to KURA ONCOLOGY INC (KURA). This can be considered as Overvalued.
Can you provide the profitability details for KURA ONCOLOGY INC?
KURA ONCOLOGY INC (KURA) has a profitability rating of 1 / 10.
Can you provide the financial health for KURA stock?
The financial health rating of KURA ONCOLOGY INC (KURA) is 6 / 10.